The loss of CD8 + T cells and the inflow of tumor-associated macrophages are associated with acquired drug resistance to metastatic melanoma.469 The development of resistance to BRAFi+MEKi in metastatic melanoma remains a major clinical challenge. The gene discussed is CD8A; the disease is metastatic melanoma.